Ann: Clarification of recent analyst report on Patent Protection, page-11

Theres a lot of specialist language and process on the whole patent issue. Putting all of that to the side, how's the biggest and most glaring issue with this saga. The research note calls this our 'key osteoarthritis patent', and our 'major patent' and that we now have no coverage, and that the wording in this latest communicaiton is likely to flow into our other applications such as pain management. Its all rubbish on so many fronts, from a company that has "made no attempt to verify their information with Paradigm or a patent expert prior to publication"!

Its good for the company to set the record straight on this, and I think a bit more practivity on the information flow in the future would help keep everyone (including the analyst!) informed and avoid these wild sentiment swings on the market. Now, hows the trial recruitment, the CEO search and the partner DD progressing...?